Literature DB >> 23261071

Hypoxaemic rescue therapies in acute respiratory distress syndrome: Why, when, what and which one?

Carol Hodgson1, Guillaume Carteaux, David V Tuxen, Andrew R Davies, Vin Pellegrino, Gilles Capellier, David J Cooper, Alistair Nichol.   

Abstract

Acute respiratory distress syndrome (ARDS) is an inflammatory condition of the lungs which can result in refractory and life-threatening hypoxaemic respiratory failure. The risk factors for the development of ARDS are many but include trauma, multiple blood transfusions, burns and major surgery, therefore this condition is not uncommon in the severely injured patient. When ARDS is severe, high-inspired oxygen concentrations are frequently required to minimise hypoxaemia. In these situations clinicians commonly utilise interventions termed 'hypoxaemic rescue therapies' in an attempt to improve oxygenation, as without these, conventional mechanical ventilation can be associated with high mortality. However, their lack of efficacy on mortality when used prophylactically in generalised ARDS cohorts has resulted in their use being confined to clinical trials and the subset of ARDS patients with refractory hypoxaemia. First line hypoxaemic rescue therapies include inhaled nitric oxide, prone positioning, alveolar recruitment manoeuvres and high frequency oscillatory ventilation, which have all been shown to be effective in improving oxygenation. In situations where these first line rescue therapies are inadequate extra-corporeal membrane oxygenation has emerged as a lifesaving second line rescue therapy. Rescue therapies in critically ill patients with traumatic injuries presents specific challenges and requires careful assessment of both the short and longer term benefits, therapeutic limitations, and specific adverse effects before their use.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute respiratory distress syndrome; Intensive care; Mechanical ventilation

Mesh:

Substances:

Year:  2012        PMID: 23261071     DOI: 10.1016/j.injury.2012.11.017

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  6 in total

1.  Impact of steroid medication before hospital admission on barotrauma in mechanically ventilated patients with acute respiratory distress syndrome in intensive care units.

Authors:  Takeshi Umegaki; Sachiyo Sakamoto; Kenichiro Nishi; Akihisa Okamoto; Aki Onose; Nobuyuki Hamano; Etsuko Yamazaki; Koh Shingu
Journal:  J Anesth       Date:  2014-02-20       Impact factor: 2.078

Review 2.  High frequency oscillatory ventilation in leptospirosis pulmonary hemorrhage syndrome: A case series study.

Authors:  Mohd Basri Mat Nor; Azrina Md Ralib; Noor Airini Ibrahim; Mohd Rasydan Abdul-Ghani
Journal:  Indian J Crit Care Med       Date:  2016-06

3.  Bedside selection of positive end-expiratory pressure by electrical impedance tomography in hypoxemic patients: a feasibility study.

Authors:  Nilde Eronia; Tommaso Mauri; Elisabetta Maffezzini; Stefano Gatti; Alfio Bronco; Laura Alban; Filippo Binda; Tommaso Sasso; Cristina Marenghi; Giacomo Grasselli; Giuseppe Foti; Antonio Pesenti; Giacomo Bellani
Journal:  Ann Intensive Care       Date:  2017-07-20       Impact factor: 6.925

4.  Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study.

Authors:  Lorenzo Ball; Denise Battaglini; Chiara Robba; Danilo Cardim; Emanuela Moncalvo; Iole Brunetti; Matteo Bassetti; Daniele R Giacobbe; Antonio Vena; Nicolò Patroniti; Patricia R M Rocco; Basil F Matta; Paolo Pelosi
Journal:  Crit Care       Date:  2021-03-19       Impact factor: 9.097

5.  Infection with Middle East respiratory syndrome coronavirus.

Authors:  Sami Alsolamy; Yaseen M Arabi
Journal:  Can J Respir Ther       Date:  2015

6.  Acute respiratory distress syndrome; A rare complication caused by usage of ruxolitinib.

Authors:  Bugra Kerget; Omer Araz; Elif Yilmazel Ucar; Metin Akgun; Leyla Sağlam
Journal:  Respir Med Case Rep       Date:  2017-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.